Engineering Glucose‐Responsive Insulin Granules with High‐Payload for Long‐Acting Glycemic Control
Advanced Materials · 2026
DOI: 10.1002/adma.202501344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Dazhi Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Hangzhou Medical College, Hangzhou, 310053, China. Hauptthemen laut MEDLINE: Insulin, Blood Glucose, Glycemic Control, Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Start-up Funding of Wenzhou Institute, UCAS, Basic Scientific Research Funds of the Department of Education of Zhejiang Province, Young Scientists Fund of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Developing high‐payload systems that dynamically respond to physiological fluctuations is crucial not only for improving the precision, safety, and efficacy of protein therapies but also for addressing biosafety concerns associated with carriers, reducing administration frequency, minimizing infection risks, and enhancing patient compliance. However, achieving precise control over protein release in the high‐payload carriers remain a major challenge. In this study, a physiology‐responsive, high‐payload insulin (Ins) granule is engineered for long‐term glucose management, using Ins as a model—an essential hormone that must be released in response to blood glucose changes for effective glycemic control in diabetic patients. The [(Ins&GOx)@Zn]@[TA&Fe] granules achieve an Ins loading capacity (LC%) exceeding 80%, significantly higher than the previously reported maximum of ≈40%. These granules extend the glucose‐regulating effect of free Ins, typically limited to 3 h, to 6 days with a single injection, without any observed risk of hypoglycemia. Long‐term administration (28 days, 4 injection cycles, 7 days injection −1 ) shows no significant physiological toxicity or immune response. This approach offers a promising strategy for developing intelligent, high‐payload delivery systems for protein‐based therapeutics, advancing more precise, safe, and patient‐compliant treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Hangzhou Medical College, Hangzhou, 310053, China.
- Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, 325001, China.
- Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, 830011, China.
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
- Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
ORCID-Profile: Xingjie Zan
Förderung
- Start-up Funding of Wenzhou Institute, UCAS
- Basic Scientific Research Funds of the Department of Education of Zhejiang Province
- Young Scientists Fund of the National Natural Science Foundation of China
- Industry-University-Research Innovation Fund for Chinese Universities-Infection and Control Project
- Hangzhou Medical College Scientific and Technological Innovation Guidance Fund
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Chen, D., Yang, L., Ni, S., Jin, C., Xu, C., Zan, X., Wang, Y., & Zhu, H. (2026). Engineering Glucose‐Responsive Insulin Granules with High‐Payload for Long‐Acting Glycemic Control. Advanced Materials. https://doi.org/10.1002/adma.202501344
Vancouver
Chen D, Yang L, Ni S, Jin C, Xu C, Zan X, et al. Engineering Glucose‐Responsive Insulin Granules with High‐Payload for Long‐Acting Glycemic Control. Advanced Materials. 2026. doi:10.1002/adma.202501344
BibTeX
@article{Chen2026,
author = {Chen, Dazhi and Yang, Li and Ni, Shulan and Jin, Chaofan and Xu, Chunyi and Zan, Xingjie and Wang, Yang and Zhu, Hong},
title = {Engineering Glucose‐Responsive Insulin Granules with High‐Payload for Long‐Acting Glycemic Control},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202501344}
}
EUVIMED